← Search & browse all drugs

deanol

N06BX04

Forms & Strengths

Oral tablets 100 mg
Oral tablets 300 mg
Oral solution 10 mg/mL

Adult Dosing

300 mg once daily
600 mg divided BID (max 600 mg/day) for cognitive support
Adjust dose in renal/hepatic impairment; reduce to 150 mg QD
Use with food to improve tolerability

Pediatric Dosing

Insufficient data; not recommended in children <12 y
If used off‑label, 50 mg/kg/day divided BID not to exceed 300 mg/day; monitor closely

Indications

Mild cognitive impairment and age‑related memory decline (off‑label)
Adjunct in Alzheimer’s disease for symptomatic support (off‑label)
Attention‑deficit/hyperactivity disorder (off‑label)
Fatigue and mood enhancement in healthy adults (dietary supplement)

Mechanism of Action

Metabolized to choline → precursor for acetylcholine synthesis
Enhances phosphatidylcholine turnover in neuronal membranes
May increase cerebral blood flow via endothelial nitric oxide modulation
Exhibits mild antioxidant activity reducing lipid peroxidation

Contraindications

Known hypersensitivity to DMAE or formulation excipients
Severe hepatic or renal failure
Unstable cardiovascular disease (e.g., uncontrolled hypertension)
Pregnancy and lactation – avoid due to limited safety data

Adverse Reactions

Headache
Insomnia or vivid dreams
Gastro‑intestinal upset (nausea, dyspepsia)
Tachycardia or transient hypertension
Muscle tension or tremor
Rare skin rash

Drug Interactions

Concurrent anticholinergic agents may blunt cognitive benefits
Cholinesterase inhibitors (donepezil, rivastigmine) may have additive cholinergic effects → monitor for excess stimulation
Antihypertensive drugs – possible additive hypotensive effect when high‑dose DMAE causes vasodilation
MAO‑inhibitors – theoretical risk of hypertensive crisis; use with caution

Curated Content: Needs Vetting Before Put to Clinical Use